Latest Breaking News On - Protara therapeutics - Page 9 : comparemela.com

Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring

/PRNewswire/ DelveInsight s Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, bladder cancer.

United kingdomUnited statesEmtora biosciencesOcellaris pharmaTakara bioKlus pharmaTransthera biosciencesFidia farmaceuticiUrogen pharmaPrnewswire delveinsightAstellas pharmaShruti thakurBristol myers squibbInnocare pharmaTaizhou hanzhongEli lilly

DelveInsight Business Research, LLP: Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring

DelveInsight Business Research, LLP: Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPrnewswire delveinsightTakara bioUrogen pharmaTransthera biosciencesBristol myers squibbAstellas pharmaShruti thakurInnocare pharmaKlus pharmaOcellaris pharmaFidia farmaceuticiEli lillyTaizhou hanzhongEmtora biosciences

Protara Therapeutics (NASDAQ:TARA) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Protara Therapeutics (NASDAQ:TARA – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $23.00 target price on the stock. Protara Therapeutics Price Performance Shares of TARA traded down $0.12 during mid-day trading on Friday, hitting $2.42. The […]

Renaissance technologiesPrivium fund management united kingdom ltdProtara therapeutics incPrivium fund managementVirtu financialProtara therapeuticsFree reportGet free reportFund management united kingdom ltdProtara therapeutics dailyNasdaq taraReiterated ratingHc wainwright

H C Wainwright Sticks to Their Buy Rating for Protara Therapeutics (TARA)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Protara Therapeutics (TARA – Research Report), wit.

New yorkUnited statesAndrew feinJesse sheffermanArtara therapeutics incProtara therapeuticsResearch reportBlueprint medicinesModerate buyTara therapeutics

Protara Therapeutics (NASDAQ:TARA) Trading 6 5% Higher

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) traded up 6.5% during trading on Monday . The company traded as high as $2.54 and last traded at $2.47. 48,083 shares were traded during mid-day trading, an increase of 61% from the average session volume of 29,836 shares. The stock had previously closed at […]

Protara therapeutics incRenaissance technologiesVirtu financialPrivium fund management united kingdom ltdProtara therapeuticsGet free reportFund management united kingdom ltdProtara therapeutics dailyNasdaq tara